



Berkshire West Area Prescribing Committee

Drug Name	Ketoprofen with omeprazole (Axorid®)		
Indication under review	Treatment of rheumatoid arthritis, ankylosing spondylitis and osteoarthritis		
Policy No:	APC 072		
Date of Issue/ Date of re-issue:	January 2014/ March 2017		
Review Date:	March 2020		
Policy Statement:	Ketoprofen with omeprazole (Axorid®) is not routinely recommended for the treatment of patients with rheumatoid arthritis, ankylosing spondylitis and osteoarthritis.		
Traffic Light Status	Brown		
Key Points considered:	<ul style="list-style-type: none"> • Ketoprofen with omeprazole (Axorid®) treatment does not have significant benefits over other treatments. • This treatment is not considered to be cost effective. Given the price difference between this combination product and separate combinations of NSAIDs and proton pump inhibitors it would seem unlikely that routine use would be a cost-effective use of NHS resources within the licensed indications and outside of the licensed indications. It would certainly not be a cost effective use of NHS resources and a significant financial risk to the CCG budget. • This policy has been produced as a guide for GPs. Evidence and information was carefully considered and consulted upon by clinicians who concluded that this treatment is not a cost effective use of scarce NHS resources. There are situations where this policy may not apply to an individual patient due to their clinical exceptionality. This policy statement does not overrule an individual GPs clinical decision making and therefore each GP would be need to make the final decision on whether treatment is a cost-effective use of their CCG budget 		
References:	<ol style="list-style-type: none"> 1. SPC information accessed via www.medicines.org.uk 2. SMC information accessed via www.scottishmedicines.org.uk 3. NICE information accessed via www.NICE.org.uk 4. AWMSG information accessed via www.wales.nhs.uk 5. UKMI info accessed via www.nelm.nhs.uk 		
Date taken to APC:	1 st March 2017		
Date Ratified by GP MOC on Behalf of the Board:	15 th March 2017		

Berkshire West Area Prescribing Policies serve as a guide to clinicians. This does not overrule the clinical or budgetary responsibility of clinicians when considering treatment for individual patients.

Brown	Green	Amber	Red
These drugs have been reviewed and are not considered a cost effective use of scarce NHS resources	Medicines suitable for routine use. Primary care prescribers take full responsibility for prescribing	Medicines that should be initiated by a specialist and can be continued in primary care under a shared care agreement.	Medicines which should be prescribed by specialists only